Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

• ClinicalTrials.gov Identifier: NCT03049189
• Recruitment Status: Active, not recruiting
• First Posted: February 9, 2017
• Last Update Posted: January 18, 2023
• Sponsor: ITM Solucin GmbH
• Collaborators: ABX CRO; PSI CRO
• Information provided by (Responsible Party): ITM Solucin GmbH

Tracking Information

• First Submitted Date: January 13, 2017
• First Posted Date: February 9, 2017
• Last Update Posted Date: January 18, 2023
• Actual Study Start Date: February 2, 2017
• Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 11, 2021)

progression-free survival (PFS) [ Time Frame: 12 weeks +/- 14 days, up to 30 months ]

PFS will be assessed individually per patient from date of randomization until the date of first documented progression, assessed up to 30 months, primary outcome will be measured by CT/MRI every 12 weeks +/- 14 days

Original Primary Outcome Measures (submitted: February 7, 2017)

progression-free survival (PFS) [ Time Frame: 12 weeks +/- 14 days, up to 24 months ]

PFS will be assessed individually per patient from date of randomization until the date of first documented progression, assessed up to 24 months, primary outcome will be measured by CT/MRI every 12 weeks +/- 14 days

Current Secondary Outcome Measures (submitted: March 11, 2021)

overall survival (OS) [ Time Frame: every 3 months for a period of at least 30 months ]

OS as secondary outcome measure will be assessed per patient from date of randomization until the date of death, whichever came first

Original Secondary Outcome Measures (submitted: February 7, 2017)

overall survival (OS) [ Time Frame: every 3 months for a period of at least 24 months ]

OS as secondary outcome measure will be assessed per patient from date of randomization until the date of death, whichever came first

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
• Official Title: A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)
• Brief Summary: The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Neuroendocrine Tumors

Intervention

• Drug: 177Lu-edotreotide PRRT
  PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
  Other Names:

  • 177Lu-DOTATOC
  • 177Lu-Edo
• Drug: Everolimus
  Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
  Other Name: Afinitor
• Other: Amino-Acid Solution
  The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
  Other Name: Arginine-Lysine Solution

Study Arms

• Experimental: 177Lu-edotreotide PRRT

  177Lu-edotreotide (177Lu-DOTATOC)

  A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.

  Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)

  Interventions:

  • Drug: 177Lu-edotreotide PRRT
  • Other: Amino-Acid Solution
• Active Comparator: Everolimus

  Everolimus (Afinitor ®)

  Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)

  Intervention: Drug: Everolimus

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: June 7, 2022): 309
• Original Estimated Enrollment (submitted: February 7, 2017): 300
• Estimated Study Completion Date: June 2029
• Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET)
• Measurable disease per RECIST 1.1
• Somatostatin receptor positive (SSTR+) disease
• Progressive disease based on RECIST 1.1. criteria as evidenced by two morphological imaging examinations made with the same imaging method (either CT or MRI)

Exclusion Criteria:

• Known hypersensitivity to edotreotide or everolimus
• Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative
• Prior exposure to any peptide receptor radionuclide therapy (PRRT)
• Prior therapy with mTor inhibitors
• Prior EFR (external field radiation) to GEP-NET lesions within 90 days before randomisation or radioembolisation therapy
• Therapy with an investigational compound and/or medical device within 30 days prior to randomisation
• Indication for surgical lesion removal with curative potential
• Planned alternative therapy (for the period of study participation)
• Serious non-malignant disease
• Clinically relevant renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments
• Pregnant or breast-feeding women
• Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) or any other vulnerable population to that sense (e.g. persons institutionalised, incarcerated etc.).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Poland, South Africa, Spain, Switzerland, United Kingdom, United States

Administrative Information

• NCT Number: NCT03049189
• Other Study ID Numbers: ITM-LET-01
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: ITM Solucin GmbH
• Original Responsible Party: Same as current
• Current Study Sponsor: ITM Solucin GmbH
• Original Study Sponsor: Same as current

Collaborators

• ABX CRO
• PSI CRO

• Investigators: Not Provided
• PRS Account: ITM Solucin GmbH
• Verification Date: June 2022